Basel, Switzerland (UroToday.com) At the 2019 APCCC meeting, Rob Reiter, MD from UCLA discussed the definitions and concepts of oligometastatic prostate cancer. Certainly, over the last several years with improved imaging, this definition has become important from a terminology and treatment standpoint. According to Dr. Reiter, there are several potential pathways of oligometastasis from the primary […]
Multicentric, Prospective, Randomized Controlled Trial Comparing Best Systemic Therapy (BST) With Radical Prostatectomy or BST Alone in the Management of Men With Pauci-metastatic Prostate Cancer Condition: Prostate Cancer Intervention: Procedure: Radical prostatectomy Drug: Best systemic therapy Purpose: The aim of the study is to investigate, the effect of radical prostatectomy with extended lymphadenectomy on cancer-specific […]
Basel, Switzerland (UroToday.com) Dr. Darren Poon gave an overview of prostate cancer in the East-Asian ethnicity. This ethnicity includes China, (including Hong-Kong and Macau), Japan, Mongolia, North Korea, South Korea, and Taiwan. When assessing the taxane related adverse events in Asian prostate cancer patients, compared to the rates described in the major studies, there is […]
Basel, Switzerland (UroToday.com) Dr. Karim Fizazi’s presentation integrated the previous few presentations, summarizing how best to treat node-positive (cN+) prostate cancer patients. There are over 20 randomized controlled trials in localized and advanced prostate cancer that have been published according to Dr. Fizazi. However, none have been published in the setting of node-positive prostate cancer. […]
Basel, Switzerland (UroToday.com) At the Advanced Prostate Cancer Consensus Conference (APCCC) 2019 session on PSA recurrence after radical local therapy and oligometastatic prostate cancer, Dr. Christopher Evans from UC-Davis discussed the management of men with PSA recurrence or persistence after radical prostatectomy. Dr. Evans started by highlighting that the AUA definition of biochemical recurrence is remission […]
Basel, Switzerland (UroToday.com) Dr. Nicholas James presented on the systemic therapy options for men with node-positive hormone-sensitive prostate cancer (HSPC), including whether the primary tumor should be treated, and which treatments can be combined. It is currently known that androgen deprivation therapy (ADT) remains a fixed part of therapy, and that radiotherapy improves survival of […]
Basel, Switzerland (UroToday.com) Dr. Felix Feng from UCSF presented during the PSA Recurrence after Radical Local Therapy and Oligometastatic Prostate Cancer session at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019 by discussing the management of men with PSA recurrence after radical local radiation therapy. Dr. Feng notes that over 1.2 million patients worldwide are diagnosed […]
Basel, Switzerland (UroToday.com) As a follow-up to Dr. Stefano Fanti’s presentation on the advantages of PSMA PET-CT imaging, Dr. Ian Davis from Melbourne discussed some of the pitfalls and disadvantages of PSMA PET-CT in advanced prostate cancer imaging. Admitting that in his opinion, although 68Ga-PSMA PET-CT is great, there is a certain degree of false positives and negatives, […]
Basel, Switzerland (UroToday.com) At the Advanced Prostate Cancer Consensus Conference (APCCC) 2019 meeting, Dr. Stefano Fanti from discussed the advantages of PSMA PET-CT in advanced prostate cancer imaging, specifically the role in staging, biochemical recurrence, and therapy planning. For staging, the updated European Association of Urology guidelines do not explicitly mention PSMA PET-CT, however, do say that […]
Basel, Switzerland (UroToday.com) Dr. Declan Murphy provided a discussion on the node-positive prostate cancer session in the Advanced Prostate Cancer Consensus Conference (APCCC) in Basel, Switzerland. He began by discussing the staging of high-risk/locally advanced prostate cancer. According to the EAU guidelines, there is a strong recommendation to perform metastatic screening including at least a […]
